The treatment regimen of venetoclax and PegC led to a 33% CR, CRi, or CRh. Patients who responded to this therapy showed dephosphorylation of the translation initiation factor 4EBP1 in AML cells, leading to a decrease in cap-dependent translation. mRNA, messenger RNA.